

# Epidermal growth factor receptor in non-small cell lung cancer

Charles N. Prabhakar

Department of Respiratory Medicine, Royal Prince Alfred Hospital, NSW 2050, Australia

Correspondence to: Charles N. Prabhakar. Department of Respiratory Medicine, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia. Email: cprabhak@gmp.usyd.edu.au.

**Abstract:** Following the identification of a group of patients in the initial tyrosine kinase inhibitor (TKI) trials for lung cancer, there has been detailed focus on which patients may benefit from inhibitor therapy. This article reviews the background, genetics and prevalence of epidermal growth factor mutations in non-small cell lung cancer (NSCLC). Additionally, the prevalence in unselected patients is compared against various other reviews.

**Keywords:** Lung neoplasms; receptor; epidermal growth factor; carcinoma; non-small cell lung cancer (NSCLC)

Submitted Nov 14, 2014. Accepted for publication Dec 01, 2014.

doi: 10.3978/j.issn.2218-6751.2015.01.01

View this article at: <http://dx.doi.org/10.3978/j.issn.2218-6751.2015.01.01>

## Introduction

Lung cancer is a disease with significant burden, with nearly 2.5 million new diagnoses in 2011 contributing to almost 1.5 million deaths worldwide (1). However, no longer is lung cancer managed by distinguishing non-small cell lung cancer (NSCLC) and the associated subtypes from small cell lung cancer (SCLC), but as variety of distinct, although related, diseases each with requiring their own treatment options.

NSCLC make up approximately 85% (2) of lung cancers, which is then further broken down into three distinct histological subtypes (3); adenocarcinoma, squamous cell carcinoma and large cell carcinoma (LCC). Adenocarcinoma comprises the majority of all new lung cancer diagnosed with an associated fall in the proportion of squamous cell cancers (4,5).

Epidermal growth factor receptor (*EGFR*), is one of several somatic mutations, in NSCLC (6), which is seen more frequently in certain population groups. This population group is classically described as Asian, non-smoking females with adenocarcinoma (7-9). The interest in these mutations is due to the small molecule targeted therapies (such as erlotinib and gefitinib) available and in development, which can have significant prognostic benefits (10,11).

## The role of EGFR in NSCLC

The EGFR is a 170 kdalton member of the ErbB family of cell surface tyrosine kinases (12) and is encoded on chromosome 7. The receptor belongs to the HER/erbB family of tyrosine kinases, which include HER1 (EGFR/erbB1), HER2 (neu, erbB2), HER3 (erbB3), and HER4 (erbB4) (13). The function of the receptor is to regulate both cell proliferation and apoptosis via signal transduction pathways (14).

The EGFR is a transmembrane receptor consisting of three portions; an extracellular ligand-binding domain, a transmembrane domain and an intracellular tyrosine kinase domain (15). Activation of EGFR is achieved by the binding of a ligand [such as epidermal growth factor, transforming growth factor and neuregulins (16)] to the extracellular portion. The binding of a ligand results in receptor dimerization or heterodimerisation with related receptors [especially HER2/neu (17)] (18). Without a ligand bound to the receptor and the subsequent dimerisation there is no activity at the enzymatic site of the intracellular portion (16).

Once dimerisation occurs there is disruption of the autoinhibitory activity of the intracellular domain resulting in rapid autophosphorylation at tyrosine residues located on the intracellular portion (15,19). The phosphorylated

**Table 1** List of *EGFR* mutations in NSCLC resulting in sensitivity or resistance to first generation TKIs (21)

TKI sensitivity	Exon 18	Exon 19	Exon 20	Exon 21
Sensitive	G719C, G7119S, G7119A, V689M, N700D, E709K/Q, S720P	$\Delta$ E746-A750, $\Delta$ E746-T751, $\Delta$ E746-A750 (ins RP), $\Delta$ E746-T751 (ins A/I), $\Delta$ E746-T751 (ins VA), $\Delta$ E746-S752 (ins A/V), $\Delta$ L747-E749 (A750P), $\Delta$ L747-A750 (ins P), $\Delta$ L747-T751, $\Delta$ L747-T751 (ins P/S), $\Delta$ L747-S752, $\Delta$ L747-752 (E746V), $\Delta$ L747-752 (P753S), $\Delta$ L747-S752 (ins Q), $\Delta$ L747-P753, $\Delta$ L747-P753 (ins S), $\Delta$ S752-I759	V765A, T783A	L858R, N826S, A839T, K846R, L861Q, G863D
Resistance		D761Y	D770_N771 (ins NPG), D770_N771 (ins SVQ), D770_N771 (ins G), N771T V769L, S768I, T790M	

*EGFR*, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKIs, tyrosine kinase inhibitors.

receptor then functions to allow assembly and activation of intracellular messenger proteins (18), especially through the mammalian target of rapamycin (mTOR) (20).

Dysregulation of the EGFR leads to increased intracellular pathways activity, via tyrosine kinase autophosphorylation, resulting in directly or indirectly, cell proliferation, angiogenesis, invasion and metastasis (12).

Overexpression of the *EGFR* gene has been identified in a variety other cancers including: head and neck, ovary, cervix, bladder, oesophagus, stomach, brain, breast, endometrium, colon and lung (21). *EGFR* overexpression has been identified in between 40% to 89% of NSCLC (6,22), with highest rates seen in squamous tumours (89%) and lowest in adenocarcinomas (41%) (22).

### Tyrosine kinase domain mutations

As *EGFR* was noted to be overexpressed in NSCLC, it was felt that targeting the receptor with a tyrosine kinase inhibitor (TKI), gefitinib, would be an effective treatment for NSCLC, however this was not shown to be case (23). However, during the initial trial of gefitinib, a subgroup of patients were identified that had significant improvement in their lung and metastatic lesions (6). The identification of a particular subgroup of patients with dramatic response to TKI treatment led to molecular investigation of the EGFR pathway. This subgroup of patients was analysed separately by both Lynch *et al.* and Paez *et al.* who each showed that patients who possessed mutations in the tyrosine kinase domain of the EGFR (6,24). These mutations were shown to occur in exons 18, 19 and 21.

Analysis of the tyrosine kinase domain of the EGFR of

617 unselected lung cancer specimens by Shigematsu *et al.* identified that all mutations occurred within exons 18-21, with a prevalence of 21% (7). These mutations (listed in *Table 1*) provide sensitivity to targeted therapies, known as TKIs, such as erlotinib and gefitinib (21).

The majority of mutations in exon 21 are point mutations whereas exon 19 consists of almost entirely in-frame deletions (20). The L858R point mutation and  $\Delta$ E746-A750 comprise up to 86% of all EGFR mutations in some studies (25). Both the aforementioned mutations result in changes near the ATP cleft, which results in enhanced catalytic activity and autocatalysis of the tyrosine kinase when the receptor is not stimulated by EGF (or other ligands), with up to a three-fold increase in activity compared to the wild-type EGFR (6).

Whilst most tyrosine kinase domain mutations lead to sensitivity to TKIs (*Table 1*), mutations in exon 20 are associated with intrinsic resistance (26-31) which may account for up to 9% of all EGFR mutations (31).

While squamous cell carcinomas (SCC) rarely possess mutations in the tyrosine kinase domain of the EGFR receptor, about one-third of SCCs demonstrate amplification of the EGFR protein (2). Approximately 5% of SCC possess deletion mutations in exons 2-7 (EGFRvIII) which code for the extracellular domain of the protein (32). In the same series no adenocarcinomas possessed EGFRvIII mutation, however the extracellular domain mutations are frequently seen in SCCs of head and neck cancers (33).

### Histology

Amongst the various forms of NSCLC, adenocarcinoma, is

most commonly identified in all comers tested for EGFR mutation status (34-40). Bronchioloalveolar cell carcinoma (BAC), a subtype of adenocarcinoma, was associated in some of the early gefitinib studies (6,41) with response to treatment. As most NSCLCs do not respond to gefitinib, unless they have the activating mutation, then this would suggest that BAC is more commonly associated with EGFR mutation than other forms of adenocarcinoma. A retrospective audit of 139 NSCLC patients treated with gefitinib, by Miller *et al.*, revealed that significantly more patients, who experienced response to TKI therapy, possessed BAC features than those that did not receive a benefit from drug therapy (38% *vs.* 14%,  $P < 0.001$ ) (41).

BAC was then further divided into mucinous, non-mucinous carcinomas and mixed non-mucinous and mucinous or indeterminate in the World Health Organisation histological classification of tumour guide (3). However, since 2004, further clarification of the term BAC has occurred and subsequently recommended the discontinuation of the term BAC in preference for the following categories; adenocarcinoma *in situ*, minimally invasive adenocarcinoma (mucinous and rarely mucinous), lepidic predominant (non-mucinous), adenocarcinoma predominantly invasive with some non-mucinous lepidic components and, finally, invasive mucinous adenocarcinoma (42). The latter two are the forms of BAC formerly referred to as nonmucinous BAC and mucinous BAC respectively (42). As the studies referenced below present their data using the original nomenclature, the data will be presented using the papers author's original terms to ensure that no inappropriate interpretation is undertaken.

In analysing 141 primary NSCLC biopsies, of which 118 were adenocarcinomas from a Japanese population, Sakuma *et al.* demonstrated that 54% ( $P < 0.0001$ ) of the adenocarcinomas with EGFR mutations possessed histopathological features consistent with nonmucinous BAC (43). Similarly, Marchetti *et al.* found that the 56% ( $P = 0.00002$ ) of adenocarcinomas with EGFR mutation were BAC with all patients possessing a nonmucinous subtype (44). However, while Tam *et al.* also demonstrated that nonmucinous BAC was significantly associated with EGFR mutation (79%), only 13% of adenocarcinomas with an identified EGFR mutation were of BAC subtype (45).

Using the updated histological nomenclature from international association for the study of lung cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) (42), Yoshizawa *et al.* analysed 440 resected lung adenocarcinomas. They

demonstrated that 167 cases were positive for EGFR mutation with a high rate of features consistent with adenocarcinoma *in situ* (85.7%), minimally invasive adenocarcinoma (83.3%), lepidic (71.4%) and papillary predominant (68.5%), while there were no mutations identified in mucinous subtype tumours (46). Using the same criteria, Gahr *et al.* demonstrated that of the 101 patients with EGFR positive NSCLC (from a population of 1,122), 90% were nonmucinous adenocarcinoma, with only 22% poorly differentiated. Further divided down 65.3% of EGFR positive tumours had features consistent with non-lepidic-nonmucinous adenocarcinoma and 21.8% lepidic-nonmucinous histology (35). In a population of Korean smokers ( $n = 249$ ), of the 51% with EGFR positive NSCLC, when classifying the tumour on the major histological subtype, the most common finding was acinar (68.5%) followed by papillary (11.8%), solid (9%), lepidic (7.5%), micropapillary (1.4%) and only 1.8% falling into the invasive mucinous category (47).

While the vast majority of EGFR mutations in NSCLC are found in adenocarcinoma, the mutation is also seen in SCC and LCC. Comparing 15 studies (Table 2), the majority of which were in selected patient populations, the prevalence of EGFR mutation positive SCC lung cancer ranged between 0-14.6%, with an average of 4.9% when the 4,870 patients were combined into a single group.

## Epidemiology

The conventional phenotype of patients who develop a lung cancer that is positive for an EGFR mutation is the young, Asian, non-smoking, female with adenocarcinoma (7-9). While this does certainly appear to be the case, there are very few studies that have prospectively analysed non-selected populations of patients. The vast majority of papers, that examine the predictors and prevalence of EGFR mutations, recruit patients with advanced stage disease or who have failed alternate therapies (surgical or first-line chemotherapy). Even those studies that do not select for patient populations commonly have intrinsic selection bias, by the very fact that they recruit patients from a single country with homogenous ethnic populations.

Of the eight papers identified (35,36,39,58-62), which measured the frequency of EGFR mutations in NSCLC in unselected patients, only four clearly indicated that the data was gathered in a prospective manner (35,36,60,62). There was a range of mutation testing, with the majority of papers examining for mutations in exons 18-21, but some limiting

**Table 2** Frequency of EGFR positive mutations in different histological types of NSCLC

Paper	Year	Total patients	EGFR positive	Adenocarcinoma, n (%)	SCC (including adenosquamous cell carcinoma), n (%)	Large cell, n (%)	Other, n (%)	Comments
Takeda <i>et al.</i> (48)	2014	68	68	67 (98.5)	1 (1.5)	0 (0.0)	0 (0.0)	
Douillard <i>et al.</i> (49)	2014	1,060	106	102 (96.2)	2 (1.9)	1 (0.9)	1 (0.9)	
Sahnane <i>et al.</i> (50)	2013	46	23	22 (95.7)	0 (0.0)	0 (0.0)	1 (4.3)	
Gahr <i>et al.</i> (35)	2013	1,122	101	93 (92.1)	5 (5.0)	3 (3.0)	0 (0.0)	
Unal <i>et al.</i> (51)	2013	48	48	32 (66.7)	7 (14.6)	4 (8.3)	5 (10.4)	
Wheler <i>et al.</i> (52)	2013	39	15	13 (86.7)	2 (13.3)	0 (0.0)	0 (0.0)	
Hsiao <i>et al.</i> (53)	2013	580	124	121 (97.6)	2 (1.6)	0 (0.0)	1 (0.8)	
Cadranel <i>et al.</i> (37)	2012	307	44	32 (72.7)	4 (9.1)	0 (0.0)	7 (15.9)	One data point missing
Kim <i>et al.</i> (8)	2011	229	110	105 (95.5)	2 (1.8)	1 (0.9)	2 (1.8)	
Helland <i>et al.</i> (54)	2011	240	18	16 (88.9)	2 (11.1)	0 (0.0)	0 (0.0)	
Tanaka <i>et al.</i> (39)	2010	308	112	104 (92.9)	8 (7.1)	0 (0.0)	0 (0.0)	Adenocarcinoma included adenosquamous, SCC included other carcinomas
Wu <i>et al.</i> (26)	2008	515	23	22 (95.7)	1 (4.3)	0 (0.0)	0 (0.0)	
Tsao <i>et al.</i> (55)	2006	159	14	14 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	
Mitsudomi <i>et al.</i> (56)	2005	59	59	50 (84.7)	6 (10.2)	3 (5.1)	0 (0.0)	
Han <i>et al.</i> (57)	2005	90	17	14 (82.4)	1 (5.9)	0 (0.0)	2 (11.8)	

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma.

their investigation to only the common mutations (exon 19 deletions and L858R substitution). None of the studies examined for the effect of race on the presence or absence of the EGFR mutation.

The findings of the eight studies are listed in *Table 3* (individual studies were excluded from analysis in the case of missing data).

### EGFR prevalence

The prevalence of the various EGFR mutations tested for was 13.9% of the 7,595 patients with the highest prevalence (36.4%) of mutations seen in the single study conducted in Japan.

### Smoking

In those patients with the EGFR mutation, nearly 60% of patients were identified as never-smokers [or less than

20 years in one study (39)]. The prevalence of never smokers with the mutation was 42%, whereas the mutation was still identified in 10.7% of current or former smokers. The variation of the mutation presence was identified as significant in 5 of the 6 studies where statistical analysis was performed.

### Sex

In the EGFR mutation group, 64.9% of the patients were female, while the prevalence of the mutation overall was 25.8% for females but only 12.2% for males. This was statistically significant for all studies that tested for significance.

### Age

No correlation with age and the presence or absence of the mutation was identified.

**Table 3** Studies which analysed all comers for *EGFR* mutation positive NSCLC

Study	Year	Country	Total patients	<i>EGFR</i> positive	Female		Males		Never smokers		Smokers or former smoker	
					<i>EGFR</i> positive	WT	<i>EGFR</i> positive	WT	<i>EGFR</i> positive	WT	<i>EGFR</i> positive	WT
Gahr <i>et al.</i> (35)	2013	Germany	1,201	118	81	385	37	698	38	118	22	506
Locatelli-Sanchez <i>et al.</i> (36)	2013	French	753	121	76	210	45	422	73	NA	48	NA
Paik <i>et al.</i> (59)	2012	United States	675	164	77	329	48	182	110	183	54	328
D'Angelo <i>et al.</i> (62)	2011	United States	2,142	503	346	969	157	670	302	278	201	1,361
Tanaka <i>et al.</i> (39)	2010	Japan	308	112	60	41	52	155	59	37	43	150
Rosell <i>et al.</i> (60)	2009	Spain	2,105	350	244	570	106	1,181	231	381	116	1,266
Fontanini <i>et al.</i> (61)	2009	Italy	411	52	37	139	15	220	14	38	16	149
Beau-Faller <i>et al.</i> (58)	2014	France	10,117	1,047	NA	NA	NA	NA	NA	NA	NA	NA

*EGFR*, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; WT, wild type; NA, not available.

**Table 4** Prevalence of *EGFR* mutation

Study	Prevalence of <i>EGFR</i> mutation			
	Males (%)	Females (%)	Never-smokers (%)	Smokers (%)
Shigematsu <i>et al.</i> (7)	14	42	51	10
Lindeman <i>et al.</i> (non Asians) population (63)	18	28	45	15
Lindeman <i>et al.</i> (Asian population) (63)	32	58	58	26
Mitsudomi <i>et al.</i> (64)	10	38	47	7
Summary of Table 3	12.2	25.8	42.2	10.7

The final row contains a summary of the data obtained from the studies listed in Table 3. *EGFR*, epidermal growth factor receptor.

### Tumour type

In those studies where enrolment criteria were not limited to adenocarcinomas, only 3-9% of tumours identified did not possess histology consistent with adenocarcinoma. The analysis of exact tumour type could be limited in these studies as histological analysis can be difficult in cytology only specimens (such as obtained with fine needle aspiration). Only one of the studies indicated the source of tumour specimens used in mutation analysis.

### Discussion

When Lindeman *et al.* analysed the *EGFR* mutation prevalence rate, divided by race from multiple previous studies, they found that amongst the Asian/Indian population the prevalence was 52% when compared to only 24%

amongst Caucasians (63). Shigematsu *et al.*, in multi-nationality study (primarily South East Asia and Caucasians) of patients with resectable disease found an overall mutation prevalence of 23% (7). However, when divided by race the mutation rate amongst Australians and North Americans was 7% and 14% respectively, whereas the mutation rate in Asian countries was as high as 34% in the Taiwanese population.

It is difficult to resolve the wildly varying prevalence of the *EGFR* mutation in the above studies. The analysis performed in this paper on an unselected population of 17,712 mainly European and American patients is close to Shigematsu *et al.* overall prevalence calculation. When Lindeman *et al.*, Shigematsu *et al.* and this papers analysis are compared (Table 4) the overall prevalence in the unselected cohort (this study) is similar to that of the non-Asian population. The final row in Table 4 was obtained by calculating the prevalence of each stated factor in the

studies listed in *Table 3* (studies with incomplete data were excluded from individual analyses).

The prevalence of the individual sub-populations (males, females, never-smokers and smokers) are similar between the three papers when Caucasian population is considered. This suggests that the EGFR mutation is far more prevalent in Asian populations than Caucasians. Logistic regressions have only demonstrated that a low smoking history and adenocarcinoma histology are significant independent predictors of EGFR mutation status, but not sex nor age (39).

## Conclusions

EGFR mutations are significant drivers in NSCLC, especially amongst Asian females who are never-smokers with adenocarcinoma histology. However 10% of patients with EGFR mutant NSCLC have some degree of smoking history and 12% are male. Simple choosing to only mutation test patients who fit a single phenotype will miss a significant proportion of suffers who may benefit from small molecule therapy.

Current studies on the prevalence of the mutation tend to focus on a single race and many do not test for the presence of the mutation in all lung cancer stages. Despite smoking remaining the highest risk for lung cancer (5,65), there is a rising incidence of adenocarcinoma in non-smokers (66). Having an accurate model of who may develop EGFR mutation NSCLC may allow prognostic benefits with targeted therapies.

## Acknowledgements

*Disclosure:* The author declares no conflict of interest.

## References

- Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin* 2011;61:69-90.
- Herbst RS, Heymach JV, Lippman SM. Lung cancer. *N Engl J Med* 2008;359:1367-80.
- Travis WD, Brambilla E, Konrad Müller-Hermelink H, et al. eds. *Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart*. Lyon: IARC Press, 2004:1.
- Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. *Int J Cancer* 2005;117:294-9.
- Boyle P, Levin B. eds. *World Cancer Report 2008*. World Health Organization, 2008:1.
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129-39.
- Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 2005;97:339-46.
- Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. *Cancer* 2012;118:729-39.
- Usui K, Ushijima T, Tanaka Y, et al. The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases. *Pulm Med* 2011;2011:290132.
- Antonicelli A, Cafarotti S, Indini A, et al. EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. *Int J Med Sci* 2013;10:320-30.
- Cadranel J, Ruppert AM, Beau-Faller M, et al. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. *Crit Rev Oncol Hematol* 2013;88:477-93.
- Ciardello F, De Vita F, Orditura M, et al. The role of EGFR inhibitors in nonsmall cell lung cancer. *Curr Opin Oncol* 2004;16:130-5.
- da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. *Annu Rev Pathol* 2011;6:49-69.
- Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. *Clin Cancer Res* 2005;11:1167-73.
- Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. *N Engl J Med* 2005;353:172-87.
- Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. *Eur J Cancer* 2001;37 Suppl 4:S3-8.
- Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. *Mol Cell Biol* 1996;16:5276-87.
- Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell* 2010;141:1117-34.
- Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor-protein kinase interactions. *Prog Clin Biol Res* 1981;66 Pt A:557-67.

20. Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. *Lab Invest* 2014;94:129-37.
21. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer* 2007;7:169-81.
22. Al Olayan A, Hussaini Al H, Jazieh AR. The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer. *J Infect Public Health* 2012;5 Suppl 1:S50-60.
23. Bailey R, Kris M, Wolf M, et al. O-242 Gefitinib ("Iressa," ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. *Lung Cancer* 2003;41:S71.
24. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497-500.
25. Sakurada A, Shepherd FA, Tsao MS. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations. *Clin Lung Cancer* 2006;7:S138-44.
26. Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. *Clin Cancer Res* 2008;14:4877-82.
27. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. *PLoS Med* 2005;2:e313.
28. Yuza Y, Glatt KA, Jiang J, et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. *Cancer Biol Ther* 2007;6:661-7.
29. Pallan L, Taniere P, Koh P. Rare EGFR Exon 20 S768I Mutation Predicts Resistance to Targeted Therapy: A Report of Two Cases. *J Thorac Oncol* 2014;9:e75.
30. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26.
31. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. *Mol Cancer Ther* 2013;12:220-9.
32. Ji H, Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. *Proc Natl Acad Sci USA* 2006;103:7817-22.
33. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. *Clin Cancer Res* 2006;12:5064-73.
34. Kim TJ, Park CK, Yeo CD, et al. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. *J Surg Oncol* 2014;110:245-51.
35. Gahr S, Stoehr R, Geissinger E, et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. *Br J Cancer* 2013;109:1821-8.
36. Locatelli-Sanchez M, Couraud S, Arpin D, et al. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes. *Lung* 2013;191:491-9.
37. Cadranet J, Mauguen A, Faller M, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). *J Thorac Oncol* 2012;7:1490-502.
38. Smits AJJ, Kummer JA, Hinrichs JWJ, et al. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. *Cell Oncol (Dordr)* 2012;35:189-96.
39. Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. *Int J Cancer* 2010;126:651-5.
40. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012;13:239-46.
41. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. *J Clin Oncol* 2004;22:1103-9.
42. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011;6:244-85.
43. Sakuma Y, Matsukuma S, Yoshihara M, et al.

- Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. *Am J Clin Pathol* 2007;128:100-8.
44. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. *J Clin Oncol* 2005;23:857-65.
  45. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. *Clin Cancer Res* 2006;12:1647-53.
  46. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. *J Thorac Oncol* 2013;8:52-61.
  47. Sun PL, Seol H, Lee HJ, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. *J Thorac Oncol* 2012;7:323-30.
  48. Takeda M, Okamoto I, Nakagawa K. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib. *J Thorac Oncol* 2014;9:200-4.
  49. Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. *Br J Cancer* 2014;110:55-62.
  50. Sahnane N, Gueli R, Tibiletti MG, et al. Pyrosequencing for EGFR mutation detection: diagnostic accuracy and clinical implications. *Diagn Mol Pathol* 2013;22:196-203.
  51. Unal OU, Oztop I, Calibasi G, et al. Relationship between Epidermal Growth Factor Receptor Gene Mutations and Clinicopathological Features in Patients with Non-Small Cell Lung Cancer in Western Turkey. *Asian Pac J Cancer Prev* 2013;14:3705-9.
  52. Wheeler J, Falchook G, Tsimberidou AM, et al. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. *Oncotarget* 2013;4:772-84.
  53. Hsiao SH, Liu HE, Lee HL, et al. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders. *PLoS ONE* 2013;8:e83266.
  54. Helland Å, Skaug HM, Kleinberg L, et al. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. *J Thorac Oncol* 2011;6:947-50.
  55. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. *J Thorac Oncol* 2006;1:231-9.
  56. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. *J Clin Oncol* 2005;23:2513-20.
  57. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. *J Clin Oncol* 2005;23:2493-501.
  58. Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. *Ann Oncol* 2014;25:126-31.
  59. Paik PK, Johnson ML, D'Angelo SP, et al. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. *Cancer* 2012;118:5840-7.
  60. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med* 2009;361:958-67.
  61. Boldrini L, Ali G, Gisfredi S, et al. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. *Oncol Rep* 2009;22:683-91.
  62. D'Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. *J Clin Oncol* 2011;29:2066-70.
  63. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer,



- and Association for Molecular Pathology. *J Mol Diagn* 2013;15:415-53.
64. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. *Int J Clin Oncol* 2006;11:190-8.
65. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. *BMJ* 2010;340:b5569.
66. Boffetta P, Järnholm B, Brennan P, et al. Incidence of lung cancer in a large cohort of non-smoking men from Sweden. *Int J Cancer* 2001;94:591-3.

**Cite this article as:** Prabhakar CN. Epidermal growth factor receptor in non-small cell lung cancer. *Transl Lung Cancer Res* 2015;4(2):110-118. doi: 10.3978/j.issn.2218-6751.2015.01.01